- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04239963
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
Study Overview
Status
Conditions
Detailed Description
Major Depressive Disorder (MDD) participants with treatment-resistant depression (TRD) will be recruited from McLean's Ketamine clinic. Suitability for Ketamine treatment will be determined as typically done by the service - through evaluation by the clinicians on the staff of the Ketamine Service who perform psychiatric consultations and assessments for Ketamine suitability. Potential subjects will be informed about the study only after they have received a positive consultation at the clinic and have already agreed to receive the treatment.
This study consists of a set of questionnaires, urine drug screen, and electroencephalogram (EEG) recordings.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: David Crowley, ALM
- Phone Number: 617-855-4432
- Email: djcrowley@mclean.harvard.edu
Study Contact Backup
- Name: Sarah Woronko, BA
- Phone Number: 617-855-4431
- Email: sworonko@mclean.harvard.edu
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Recruiting
- McLean Hospital
-
Contact:
- Jason Scott, BA
- Phone Number: 617-855-2247
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria (MDD Subjects):
- All genders, races, and ethnic origins, aged between 18 and 70;
- DSM-5 diagnostic criteria for MDD (diagnosed with the use of the Structured Clinical Interview for DSM-5 (SCID-5));
- A score of ≥32 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30).
- Capable of providing written informed consent, and fluent in English;
- Right-handed;
- Treatment Resistant (as assessed using the MGH Antidepressant Response Questionnaire)
- Have already decided to receive ketamine treatment as part of their standard clinical care
Inclusion Criteria (Control Subjects):
- All genders, races, and ethnic origins, aged between 18 and 70;
- Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (SCID-I/NP);
- A baseline Quick Inventory of Depressive Symptomatology (QIDS) score ≤ 5;
- A baseline Hamilton Depression Rating Scale (HDRS) score ≤ 7;
- Capable of providing written informed consent, and fluent in English;
- Right-handed;
- No first-degree relative with mood or psychotic disorder.
Exclusion Criteria (All Subjects):
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease;
- History of seizure disorder;
- History or current diagnosis of any of the following DSM-5 psychiatric illnesses: schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, substance abuse disorder;
- Clinical or laboratory evidence of hypothyroidism, hyperthyroidism, or other thyroid disorder that is not controlled by medication;
- Substance use assessed by physician as dangerous for ketamine treatment;
- Untreated glaucoma;
- Complex post-traumatic stress disorder (PTSD) with dissociation;
- Patients with a lifetime history of electroconvulsive therapy (ECT).
- Participants with a lifetime history of ketamine use.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Healthy Controls
Subjects who have no history of clinical depression or other psychological disorder
|
Current MDD
Subjects experiencing a current episode of Major Depressive Disorder.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feedback-related positivity (FRP) amplitudes over frontocentral scalp regions in response to rewarded trials versus no-reward trials
Time Frame: Baseline
|
Relative FRP response is the primary outcome measure for the probabilistic reward task (PRT).
|
Baseline
|
Event-related negativity (ERN) amplitudes over frontocentral scalp regions in response to correct trials versus incorrect trials.
Time Frame: Baseline
|
Relative ERN response is the primary outcome measure for the flanker task.
|
Baseline
|
Behavioral Performance on the Probabilistic Reward Task (PRT)
Time Frame: Baseline
|
The Probablilistic Reward Task operationalizes positive reinforcement learning
|
Baseline
|
Behavioral Performance on the Flanker Task
Time Frame: Baseline
|
The Flanker Task is a cognitive task that measures response inhibition to assess the ability to suppress responses that are inappropriate in a particular context.
|
Baseline
|
Rumination
Time Frame: Baseline
|
Severity of rumination will be assessed using the Rumination Response Scale (RRS).
The RRS has a minimum score of 22 and a maximum score of 88.
Higher scores indicate higher degrees of ruminative symptoms.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Diego Pizzagalli, PhD, McLean Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P003371
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain